CoChat

Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome

Open access
Chisholm, Jeffrey W., Goldfine, Allison B., Dhalla, Arvinder K., Braunwald, Eugene, Morrow, David A., Karwatowska-Prokopczuk, Ewa, Belardinelli, Luiz · 2010 · Diabetes Care

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We determined the relationships between glycemia at randomization, concurrent antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study. Ranolazine is a novel first-in-class drug approved for treating angina pectoris. RESEARCH DESIGN AND METHODS: Randomization and 4-month glycemic and antidiabetes drug usage data from MERLIN were analyzed using Spotfire and SAS version 9.1 software. RESULTS: In patients with diabetes and A1C of ≥8–10% at randomization (n = 171), there was an absolute A1C reduction in the ranolazine group of 1.2% (95% CI −1.4 to −1.0), and the placebo-adjusted (n = 182) decrease in A1C by ranolazine was 0.59% (95% CI −0.99 to −0.20, P < 0.001). In patients with FPG of 150–400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147) reduced FPG by 25.7 mg/dl (95% CI −43.3 to −8.1, P = 0.001). When changes in either A1C or FPG were correlated to A1C or FPG at randomization, the slopes were significantly steeper for ranolazine than placebo (A1C, P = 0.046; FPG, P < 0.001), indicating that lowering of A1C and FPG by ranolazine is related to hyperglycemia at randomization. Ranolazine, compared with placebo, was not associated with serious hypoglycemic events, associated with significant changes in concurrent antidiabetic therapy, or dependent on a history of angina. CONCLUSIONS: Ranolazine, when added to concurrent antidiabetes treatment, lowers FPG and A1C in patients with cardiovascular disease and poorly controlled diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-2334

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relationship between glycemia at randomization and lowering of A1C and FPG by ranolazine in patients with a history of diabetes. A: In a cell means model, with parameters for combinations of treatment, A1C category, and diabetes, the placebo-adjusted effect of ranolazine on A1C was −0.28% (95% CI −0.55 to 0.003, P = 0.045) for patients with A1C 6 to <8% and −0.59% (−0.99 to −0.20, P < 0.001) for patients with A1C ≥8–10%. B: In a cell means model, with parameters for combinations of treatment, FPG category, and diabetes, the placebo-adjusted effect on FPG for these patients was 6.8 mg/dl (95% CI −8.8 to 22.3, P = 0.677) for patients with FPG <150 mg/dl and −25.7 mg/dl (−43.3 to −8.1, P = 0.001) for patients with FPG ≥150–400 mg/dl. Changes in A1C and FPG at month 4 are summarized by mean, associated 95% CI, and number of patients (n). C: Relationship between A1C at randomization and the change in A1C at month 4. The slope for placebo was −0.31 (95% CI −0.41 to −0.21), R = 0.26 and n = 558. For ranolazine, the slope was −0.44 (−0.53 to −0.36), R = 0.41 and n = 508. The slopes were significantly different (P = 0.045). D: Relationship between FPG at randomization and the change in FPG at month 4. The slope for placebo was −0.55 (95% CI −0.64 to −0.46), R = 0.54 and n = 328. For ranolazine, the slope was −0.81 (−0.89 to −0.73), R = 0.76 and n = 310. The slopes were significantly different (P < 0.001). Least squares regression was performed by Graphpad Prism 5.0, and the best-fit line and 95% CI for the fit are shown for each group. Similar results were obtained using an ANCOVA model with a term for treatment, A1C or FPG at randomization, and the interaction of treatment.
Figure 1 Relationship between glycemia at randomization and lowering of A1C and FPG by ranolazine in patients with a history of diabetes. A: In a cell means model, with parameters for combinations of treatment, A1C category, and diabetes, the placebo-adjusted effect of ranolazine on A1C was −0.28% (95% CI −0.55 to 0.003, P = 0.045) for patients with A1C 6 to <8% and −0.59% (−0.99 to −0.20, P < 0.001) for patients with A1C ≥8–10%. B: In a cell means model, with parameters for combinations of treatment, FPG category, and diabetes, the placebo-adjusted effect on FPG for these patients was 6.8 mg/dl (95% CI −8.8 to 22.3, P = 0.677) for patients with FPG <150 mg/dl and −25.7 mg/dl (−43.3 to −8.1, P = 0.001) for patients with FPG ≥150–400 mg/dl. Changes in A1C and FPG at month 4 are summarized by mean, associated 95% CI, and number of patients (n). C: Relationship between A1C at randomization and the change in A1C at month 4. The slope for placebo was −0.31 (95% CI −0.41 to −0.21), R = 0.26 and n = 558. For ranolazine, the slope was −0.44 (−0.53 to −0.36), R = 0.41 and n = 508. The slopes were significantly different (P = 0.045). D: Relationship between FPG at randomization and the change in FPG at month 4. The slope for placebo was −0.55 (95% CI −0.64 to −0.46), R = 0.54 and n = 328. For ranolazine, the slope was −0.81 (−0.89 to −0.73), R = 0.76 and n = 310. The slopes were significantly different (P < 0.001). Least squares regression was performed by Graphpad Prism 5.0, and the best-fit line and 95% CI for the fit are shown for each group. Similar results were obtained using an ANCOVA model with a term for treatment, A1C or FPG at randomization, and the interaction of treatment.CC BY-NC-ND · PubMed Central
Figure 2 Effect of concurrent antidiabetes drug treatment on patients treated with ranolazine reaching an A1C goal of ≤7%. Patients with a history of diabetes who were hyperglycemic at randomization (A1C >7%) were grouped by drug treatment. These patients were reexamined at 4 months and categorized as responders if A1C was ≤7%. OR for hyperglycemic patients in each group to reach an A1C ≤7% was calculated using a logistics analysis model (SAS software, Cary, NC). Data are plotted as OR (95% CI). Ins, insulin.
Figure 2 Effect of concurrent antidiabetes drug treatment on patients treated with ranolazine reaching an A1C goal of ≤7%. Patients with a history of diabetes who were hyperglycemic at randomization (A1C >7%) were grouped by drug treatment. These patients were reexamined at 4 months and categorized as responders if A1C was ≤7%. OR for hyperglycemic patients in each group to reach an A1C ≤7% was calculated using a logistics analysis model (SAS software, Cary, NC). Data are plotted as OR (95% CI). Ins, insulin.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Dhalla, 2008, Ranolazine increases glucose stimulated insulin secretion in rats, J Am Coll Cardiol, 51, A321

Cited by

Metadata

Authors
Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L.
Affiliations
  • Gilead Sciences (United States) (US)
  • Joslin Diabetes Center (US)
  • TIMI Study Group, Brigham and Women's Hospital and Department of Medicine, Boston, Massachusetts;
  • Brigham and Women's Hospital (US)
  • Division of Cardiovascular Therapeutics, Gilead Sciences, Palo Alto, California;
Corresponding author
Chisholm, Jeffrey W.
Venue
Diabetes Care
Published
2010-03-31
Volume
33
Issue
6
Pages
1163-1168
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2130710856
Cited by
78
References
25
Citations by year
2026: 1 · 2025: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 2 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 13 · 2012: 4
FWCI
6.29
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Gilead Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
ranolazine, glycemic control, HbA1c, fasting blood glucose, hyperglycemia, non-ST-elevation acute coronary syndrome, diabetes mellitus, antidiabetic therapy, hypoglycemia, angina pectoris, cardiovascular disease
MeSH terms
Ranolazine, Acetanilides, Aged, Blood Glucose, Enzyme Inhibitors, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Piperazines, Placebo Effect, Acute Coronary Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.